Get started
Author

Anjali Prasad

Institution: Mayo Clinic
ORCID: 0009-0007-4233-1384
Observed ORCID: 0009-0007-4233-1384
OpenAlex ID: A5085865684
Understanding Differences in Administrative and Audited Patient Data in Cardiac Surgery: Comparison of the University HealthSystem Consortium and Society of Thoracic Surgeons Databases
2016 · Anjali Prasad, Meghana R. Helder, et al. · Journal of the American College of Surgeons · 22
Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer
2026 · Anjali Prasad, Scott H. Kaufmann, et al. · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 4
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer
2026 · Julie R. Duffield, Xiaonan Hou, et al. · Science Translational Medicine · 4
An ATM D-compartmentalization in DNA damage response
2023 · Anjali Prasad, Arun Kanakkanthara · Trends in Cell Biology · 3
Abstract 4538: Brigatinib induces synergy with PARP inhibitors through dual inhibition of FAK and EphA2 in high-grade serous ovarian carcinoma
2024 · Julie R. Duffield, Xiaonan Hou, et al. · Cancer Research · 1
Impact of Medical Therapy on Late Morbidity and Mortality After Aortic Aneurysm Repair for Aortitis
2018 · Anjali Prasad, Meghana R.K. Helder, et al. · The Annals of Thoracic Surgery · 1
The surgical management of lung cancer in the United Kingdom between 2004 and 2009
2013 · Jessica Gubbin, Zoe Barber, et al. · Journal of Thoracic and Cardiovascular Surgery · 1
PDF
Abstract A024: A PARP-inhibitor-induced early adaptive survival response is tackled through depletion of FRA1 by brigatinib in high-grade serous ovarian carcinoma
2025 · Julie R. Duffield, Xiaonan Hou, et al. · Cancer Research
Works count: 8
Citation count: 36
H-index: 3
I10-index: 1
Year
Topic
Type